Based on the involvement of CXCR4 in various disease processes, such as cancer metastases, HIV infection or inflammatory diseases, multiple drugs targeting CXCR4 are currently under development and the CXCR4 antagonist AMD3100 is already approved by the Federal Drug Administration to mobilize hematopoietic stem cells in cancer patients1–5. This evidence concerns the gene CXCR4 and HIV infectious disease.